Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Goodwill & Intangibles: 2010-2024

Historic Goodwill & Intangibles for China Pharma Holdings (CPHI) over the last 15 years, with Dec 2024 value amounting to $6.7 million.

  • China Pharma Holdings' Goodwill & Intangibles rose 101.17% to $8.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.8 million, marking a year-over-year increase of 101.17%. This contributed to the annual value of $6.7 million for FY2024, which is 105.68% up from last year.
  • Latest data reveals that China Pharma Holdings reported Goodwill & Intangibles of $6.7 million as of FY2024, which was up 105.68% from $3.3 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Goodwill & Intangibles registered a high of $6.7 million during FY2024, and its lowest value of $147,841 during FY2021.
  • Its 3-year average for Goodwill & Intangibles is $3.9 million, with a median of $3.3 million in 2023.
  • Its Goodwill & Intangibles has fluctuated over the past 5 years, first soared by 2,416.31% in 2020, then plummeted by 97.14% in 2021.
  • Yearly analysis of 5 years shows China Pharma Holdings' Goodwill & Intangibles stood at $5.2 million in 2020, then slumped by 97.14% to $147,841 in 2021, then soared by 1,122.59% to $1.8 million in 2022, then spiked by 80.10% to $3.3 million in 2023, then soared by 105.68% to $6.7 million in 2024.